Product Code: RP-ID-10012994 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10012994
Market Overview:
Global Next Generation Cancer Diagnostics Market Size Study, By Technology (NGS, LOAC & RT-PCR), By Application (CTC, Biomarker, Proteomic), By Cancer Type (Lung, Breast), By Function Companion Diagnostics) and Regional Forecasts, 2017-2025
Global Next Generation Cancer Diagnostics Market to reach USD 14.5 billion by 2025.
Global Next Generation Cancer Diagnostics Market is valued approximately USD 5.8 billion in 2016 and is expected to grow at 16.5% CAGR during the forecast period. Owing to the early diagnosis and more précised prognosis of various types of cancer, the next generation cancer diagnostics are gaining faster adoption. Moreover, increasing cases of oncology and advancements in genomics research are primarily driving the market growth.
The objective of the study is to define market sizes of different segments & countries in previous years and to forecast the values to the next eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry with respect to each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as drivers & restraining factors which will define the future growth of the market. Additionally, it will also incorporate the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the global infertility treatment market are given below:
Technology:
 NGS-based cancer diagnostics
 qPCR & Multiplexing
 Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
 Protein microarrays-based cancer diagnostics
 DNA microarrays-based cancer diagnostics
Type:
 Lung Cancer
 Breast Cancer
 Colorectal Cancer
 Cervical Cancer
 Others
Applications:
 Biomarker Development
 CTC Analysis
 Proteomic Analysis
 Epigenetic Analysis
 Genetic Analysis
Functions:
 Therapeutic Monitoring
 Companion Diagnostics
 Prognostic Diagnostics
 Cancer Screening
 Risk Analysis
Regions:
 North America
o U.S.
o Canada
 Europe
o UK
o Germany
o France
 Asia Pacific
o China
o India
o Japan
 Rest of the World
Furthermore, the years considered for the study are as follows:
Historical year - 2015
Base year – 2016
Forecast period – 2017 to 2025
Some of the key manufacturers involved in the market are; Novartis AG, F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Abbott , GE Healthcare , Thermo Fisher Scientific, Inc.
Target Audience of the Next Generation Cancer Diagnostics Market Study
 Key Consulting Companies & Advisors
 Large, medium-sized, and small enterprises
 Venture capitalists
 Value-Added Resellers (VARs)
 Third-party knowledge providers
 Investment bankers
 Investors
Please note, that owing to the criticality of the Next Generation Cancer Diagnostic industry and rapidly changing market attributes, we are the middle of updating the report. The final report may require 2 to 3 working days post-confirmation in o
Almac Group
Cepheid
F. Hoffmann-La Roche Ltd
GE Healthcare
Illumina, Inc.
Janssen Global Services, LLC
Koninklijke Philips N.V.
Novartis AG
Perkin Elmer, Inc.
Qiagen
Thermo Fisher Scientific, Inc.
Related Reports
Proof of Quality & Reliability
